

# Can Sarisozen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4304924/publications.pdf>

Version: 2024-02-01

33  
papers

1,409  
citations

304743  
22  
h-index

414414  
32  
g-index

34  
all docs

34  
docs citations

34  
times ranked

2651  
citing authors

#	ARTICLE	IF	CITATIONS
1	The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 88, 539-550.	4.3	138
2	Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors. <i>International Journal of Pharmaceutics</i> , 2009, 371, 170-176.	5.2	135
3	Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 105, 40-49.	4.3	95
4	Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 108, 54-67.	4.3	89
5	Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?. <i>Journal of Oncological Science</i> , 2017, 3, 52-56.	0.1	88
6	Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 136, 18-28.	4.3	81
7	Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNAâ€³4a Coâ€³Delivery Triggered by Dual Stimuli in Tumor Tissue. <i>Small</i> , 2016, 12, 4837-4848.	10.0	79
8	Transferrin-Targeted Polymeric Micelles Co-loaded with Curcumin and Paclitaxel: Efficient Killing of Paclitaxel-Resistant Cancer Cells. <i>Pharmaceutical Research</i> , 2014, 31, 1938-1945.	3.5	55
9	PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells. <i>Drug Delivery</i> , 2012, 19, 169-176.	5.7	54
10	Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: <i>In Vitro</i> Evaluation on HeLa, A2780-ADR, and H69-AR Cells. <i>Molecular Pharmaceutics</i> , 2016, 13, 428-437.	4.6	51
11	Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance. <i>Drug Delivery</i> , 2012, 19, 363-370.	5.7	50
12	Polymers in the co-delivery of siRNA and anticancer drugs to treat multidrug-resistant tumors. <i>Journal of Pharmaceutical Investigation</i> , 2017, 47, 37-49.	5.3	43
13	The reversal of multidrug resistance in ovarian carcinoma cells by co-application of tariquidar and paclitaxel in transferrin-targeted polymeric micelles. <i>Journal of Drug Targeting</i> , 2017, 25, 225-234.	4.4	41
14	Surface-engineered polyethyleneimine-modified liposomes as novel carrier of siRNA and chemotherapeutics for combination treatment of drug-resistant cancers. <i>Drug Delivery</i> , 2019, 26, 443-458.	5.7	40
15	Rosuvastatin induces apoptosis in cultured human papillary thyroid cancer cells. <i>Journal of Endocrinology</i> , 2011, 210, 105-115.	2.6	39
16	PEG-PE/clay composite carriers for doxorubicin: Effect of composite structure on release, cell interaction and cytotoxicity. <i>Acta Biomaterialia</i> , 2017, 55, 443-454.	8.3	35
17	Charge reversible hyaluronic acid-modified dendrimer-based nanoparticles for siMDR-1 and doxorubicin co-delivery. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 154, 43-49.	4.3	31
18	Recent advances in siRNA delivery. <i>Biomolecular Concepts</i> , 2015, 6, 321-341.	2.2	30

#	ARTICLE	IF	CITATIONS
19	Chitosan Coated Furosemide Liposomes for Improved Bioavailability. Journal of Biomedical Nanotechnology, 2011, 7, 426-430.	1.1	27
20	Redox-triggered intracellular siRNA delivery. Chemical Communications, 2018, 54, 6368-6371.	4.1	25
21	Cytotoxicity of Novel Redox Sensitive PEG2000-S-S-PTX Micelles against Drug-Resistant Ovarian and Breast Cancer Cells. Pharmaceutical Research, 2020, 37, 65.	3.5	25
22	A Triple Co-Delivery Liposomal Carrier That Enhances Apoptosis via an Intrinsic Pathway in Melanoma Cells. Cancers, 2019, 11, 1982.	3.7	23
23	Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey. Current Pharmaceutical Biotechnology, 2016, 17, 728-740.	1.6	22
24	Library of Cationic Polymers Composed of Polyamines and Arginine as Gene Transfection Agents. ACS Omega, 2019, 4, 2090-2101.	3.5	22
25	Cytotoxicity and <i>in vitro</i> characterization studies of synthesized Jeffamine-cored PAMAM dendrimers. Journal of Microencapsulation, 2014, 31, 127-136.	2.8	18
26	Farnesylthiosalicylic acid-loaded lipid-polyethylene glycol-polymer hybrid nanoparticles for treatment of glioblastoma. Journal of Pharmacy and Pharmacology, 2017, 69, 1010-1021.	2.4	16
27	The Cytotoxic Action of Cytochrome C/Cardiolipin Nanocomplex (Cyt-CL) on Cancer Cells in Culture. Pharmaceutical Research, 2017, 34, 1264-1275.	3.5	15
28	Development of biodegradable drug releasing polymeric cardiovascular stents and <i>in vitro</i> evaluation. Journal of Microencapsulation, 2009, 26, 501-512.	2.8	13
29	MDM2 antagonist-loaded targeted micelles in combination with doxorubicin: effective synergism against human glioblastoma via p53 re-activation. Journal of Drug Targeting, 2019, 27, 624-633.	4.4	11
30	Optimization of prednisolone acetate-loaded chitosan microspheres using a 2 <sup>3</sup> factorial design for preventing restenosis. Drug Delivery, 2010, 17, 178-186.	5.7	8
31	Novel Nanoprinting for Oral Delivery of Poorly Soluble Drugs. Methodist DeBakey Cardiovascular Journal, 2016, 12, 157-162.	1.0	6
32	Synthesis of Doxorubicin and miRNA Stimuli-Sensitive Conjugates for Combination Therapy. Methods in Molecular Biology, 2019, 1974, 99-109.	0.9	1
33	MP-2.04: Broadhesive Coated Nanoparticles Loaded with Mitomycin C for the Effective Chemotherapy of Superficial Bladder Cancer. Urology, 2008, 72, S67.	1.0	0